Showing results (1-10 of 31) with videos related to
Sort By:
Pageof 4
Cell Cycle (Georgetown, Tex.)|March 22, 2007
Fhit expression protects against HER2-driven breast tumor development: unraveling the molecular interconnectionsFrancesca Bianchi, Elda Tagliabue, Sylvie Ménard, et al.Oncogene|October 7, 2003
Biologic and therapeutic role of HER2 in cancerSylvie Ménard, Serenella Marja Pupa, Manuela Campiglio, et al.Expert Opinion on Biological Therapy|March 11, 2010
HER2 as a target for breast cancer therapyElda Tagliabue, Andrea Balsari, Manuela Campiglio, et al.Cancer Treatment Reviews|July 6, 2011
Activity and resistance of trastuzumab according to different clinical settingsElda Tagliabue, Manuela Campiglio, Serenella M Pupa, et al.Journal of the National Cancer Institute. Monographs|November 2, 2011
The HER2 World: Better Treatment Selection for Better OutcomeElda Tagliabue, Manuela Campiglio, Serenella M Pupa, et al.Cancer Research|June 5, 2007
Protein kinase Calpha determines HER2 fate in breast carcinoma cells with HER2 protein overexpression without gene amplificationAlessandra Magnifico, Luisa Albano, Stefano Campaner, et al.Journal of Cellular Physiology|March 21, 2006
Diadenosines as FHIT-ness instructorsManuela Campiglio, Francesca Bianchi, Francesca Andriani, et al.Clinical Cancer Research : an Official Journal of the American Association for Cancer Research|February 13, 2002
HER-2-positive breast carcinomas as a particular subset with peculiar clinical behaviorsSylvie Ménard, Andrea Balsari, Patrizia Casalini, et al.International Journal of Cancer|April 25, 2003
Role of proliferation in HER2 status predicted response to doxorubicinManuela Campiglio, Giulia Somenzi, Clelia Olgiati, et al.Cellular Signalling|January 18, 2003
The adaptor function of SHP-2 downstream of the prolactin receptor is required for the recruitment of p29, a substrate of SHP-2Parham Minoo, Naila Chughtai, Manuela Campiglio, et al.Pageof 4